Pharma News

US FDA grants 510(k) clearance to Bio2 Medical's Angel Catheter

  • Posted on: 27 August 2016
  • By: Shalini.Sharma

Bio2 Medical has announced that the Angel Catheter has received 510(k) clearance from the United States Food & Drug Administration (FDA). This 510(k) clearance includes a first ever, prophylactic indication for a medical device to protect critically ill patients at high-risk for pulmonary embolism (PE) and contraindicated for anticoagulation.  The Angel Catheter provides a novel alternative to IVC filters for PE protection in a vast patient population that has historically been underserved. The device is designed for bedside placement, without the need for fluoroscopic guidance, and is designed to be safely retrieved in all cases once no longer indicated.


USPTO ruling favours Mylan against Teva's Copaxone 40 mg/mL patents

  • Posted on: 26 August 2016
  • By: Shalini.Sharma

Mylan NV announced that the US Patent and Trademark Office (USPTO) has ruled in favour of Mylan in its inter partes review (IPR) proceeding and found all claims of two related Copaxone 40 mg/mL patents to be unpatentable. The US Patent Nos. are 8,232,250 and 8,399,413, which are owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd. A decision by the PTAB on Mylan's third petition seeking inter partes review of US Patent No. 8,696,302 is expected on or before September 1, 2016.


Mallinckrodt’s Synacthen® Depot IND Application Receives FDA Fast-Track Designation

  • Posted on: 26 August 2016
  • By: Shalini.Sharma

Mallinckrodt plc announced the U.S. Food and Drug Administration (FDA) has granted the company's request for a Fast Track designation for its Investigational New Drug (IND) application for Synacthen® Depot in the treatment of Duchenne muscular dystrophy (DMD). Synacthen Depot is a depot formulation of Synacthen (tetracosactide), a synthetic 24 amino acid melanocortin receptor agonist. Synacthen Depot is approved and marketed outside of the U.S. for certain autoimmune and inflammatory conditions, but has never been approved for use in patients in the U.S.


EMA accept Biocon & Mylan MAA for Proposed Biosimilar Trastuzumab

  • Posted on: 26 August 2016
  • By: Shalini.Sharma

Mylan N.V. and Biocon Ltd. announced that the European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization Application (MAA) for a proposed biosimilar Trastuzumab, which is used to treat certain HER2-positive breast and gastric cancers. This is the second biosimilar submission developed by the partnership that has been accepted for review in Europe. Last month, Mylan's MAA for the proposed biosimilar Pegfilgrastim was accepted for review by EMA.


U.S. FDA provide update on Zealand pharma’s iGlarLixi, for type 2 diabetes patients

  • Posted on: 23 August 2016
  • By: Shalini.Sharma

Zealand Pharma (Zealand) announced that Sanofi has submitted updated information on the pen delivery device for iGlarLixi to the U.S. Food and Drug Administration (FDA) as part of the New Drug Application (NDA) for the product. IGlarLixi is a once-daily, fixed-ratio combination of lixisenatide (AdlyxinTM) and insulin glargine 100 Units/mL (Lantus®) for the treatment of adults with type 2 diabetes.


Pfizer Acquire Medivation

  • Posted on: 23 August 2016
  • By: Shalini.Sharma

Pfizer Inc.  and Medivation, Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizer’s Adjusted Diluted EPS upon closing, approximately $0.05 accretive in the first full year after close with additional accretion and growth anticipated thereafter. Pfizer does not expect the transaction to impact its current 2016 financial guidance.


Pages